<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841812</url>
  </required_header>
  <id_info>
    <org_study_id>CINI-ZYLX-201809-50</org_study_id>
    <nct_id>NCT03841812</nct_id>
  </id_info>
  <brief_title>Comparation Analgesia Efficiency With Sulfentanyl and Sevoflurane</brief_title>
  <official_title>Comparation Analgesia Efficiency With Sulfentanyl and Sevoflurane Using Index of Nociception (NOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China International Neuroscience Institution</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China International Neuroscience Institution</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study purpose to compare analgesia efficiency of Sufentanyl and sevoflurane combine with
      Remifentanil &amp; propofol using index of Nociception (NOX)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Recently study found sevoflurane plays an important role through spinal nerve peptide
           receptor (NK.1R), glycine receptor (GlyR), neuron nicotinic receptor (nnAChRs),
           Methyl-1-methyl-1-day aspartate (NMDA receptor), and TRPV1 receptor (TRPV1 receptor)
           produce the analgesic efficiency.

        2. Sufentanyl was traditional opioid analgesic reagent.

        3. index of Nociception (NOX) was the objective index for analgesia This study purpose to
           compare analgesia efficiency of Sufentanyl and sevoflurane combine with Remifentanil &amp;
           propofol using index of Nociception (NOX)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactic acid concentration change</measure>
    <time_frame>24 hours</time_frame>
    <description>Lactic acid concentration was the important outcome of reflect stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>glucose concentration was the important outcome of reflect stress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nociception index change</measure>
    <time_frame>24 hours</time_frame>
    <description>Nociception index using Angle 6000A monitoring to reflect analgesic effect directly</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nociceptive Pain</condition>
  <condition>Analgesic Adverse Reaction</condition>
  <condition>Inhalant Use</condition>
  <arm_group>
    <arm_group_label>Remifentanil &amp; Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3ug/kg/min Remifentanil and 3ug/kg/min Propofol group. (Total intravenous anesthesia, TIVA). Remifentanil was analgesia reagent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane &amp; Remifentanil &amp; Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1%Sevoflurane combine with 0.3ug/kg/min Remifentanil and 3ug/kg/min Propofol group (Balance anesthesia) analgesia effect. Sevoflurane has special analgesia effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfentanyl &amp; Remifentanil &amp; Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01ug/kg/min Sulfentanyl combine with 0.3ug/kg/min Remifentanil and 3ug/kg/min Propofol group. Sulfentanyl has opioid analgesia effect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil &amp; Propofol</intervention_name>
    <description>0.3ug/kg/min remifentanil &amp; 3mg/kg/min propofol</description>
    <arm_group_label>Remifentanil &amp; Propofol</arm_group_label>
    <arm_group_label>Sevoflurane &amp; Remifentanil &amp; Propofol</arm_group_label>
    <arm_group_label>Sulfentanyl &amp; Remifentanil &amp; Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>1% Sevoflurane applyed during intra-operation.</description>
    <arm_group_label>Sevoflurane &amp; Remifentanil &amp; Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfentanyl</intervention_name>
    <description>0.01ug/kg/min Sulfentanyl infused during operation</description>
    <arm_group_label>Sulfentanyl &amp; Remifentanil &amp; Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  only elective coronary artery bypass graft (CABG) surgery patients were enrolled,
             ranging in age from 30 to 85 years, with an American Society of Anesthesiologists
             (ASA) Physical Status score of 2 to 4 and a body mass index (BMI) ranging from 18.5 to
             40 kg/m2.

        Exclusion criteria: (1) patients with Alzheimer's disease, (2) implanted pacemaker, (3)
        psychiatric diseases, (4) epilepsy, and (5) autonomic nervous system disorders which might
        affect the EEG. Patients under surgery lasting &gt;6 hours, and CPB lasting &gt;3 hours, usually
        indicative of bad outcome, were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke Huang, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanghai Cui, PHD</last_name>
    <phone>83199270</phone>
    <phone_ext>83199270</phone_ext>
    <email>1055885750@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tianlong Wang, Doctor</last_name>
    <phone>83199333</phone>
    <phone_ext>83199333</phone_ext>
    <email>w_tl5595@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Wang, doctor</last_name>
      <phone>83199305</phone>
      <email>wxh15910851623@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

